186 related articles for article (PubMed ID: 22517003)
61. Revisiting the Roles of Pro-Metastatic EpCAM in Cancer.
Mohtar MA; Syafruddin SE; Nasir SN; Low TY
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32046162
[TBL] [Abstract][Full Text] [Related]
62. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
[TBL] [Abstract][Full Text] [Related]
63. Increased EpCAM expression in malignant insulinoma: potential clinical implications.
Raffel A; Eisenberger CF; Cupisti K; Schott M; Baldus SE; Hoffmann I; Aydin F; Knoefel WT; Stoecklein NH
Eur J Endocrinol; 2010 Feb; 162(2):391-8. PubMed ID: 20097833
[TBL] [Abstract][Full Text] [Related]
64. Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy.
Yanamoto S; Kawasaki G; Yoshitomi I; Iwamoto T; Hirata K; Mizuno A
Oral Oncol; 2007 Oct; 43(9):869-77. PubMed ID: 17207659
[TBL] [Abstract][Full Text] [Related]
65. The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer.
Karabulut S; Tas F; Tastekin D; Karabulut M; Yasasever CT; Ciftci R; Güveli M; Fayda M; Vatansever S; Serilmez M; Disci R; Aydıner A
Tumour Biol; 2014 Sep; 35(9):8849-60. PubMed ID: 24891186
[TBL] [Abstract][Full Text] [Related]
66. MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer.
Cheng JP; Yan Y; Wang XY; Lu YL; Yuan YH; Jia J; Ren J
Chin J Cancer; 2011 Jan; 30(1):54-61. PubMed ID: 21192844
[TBL] [Abstract][Full Text] [Related]
67. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
[TBL] [Abstract][Full Text] [Related]
68. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients.
Lu J; Fan T; Zhao Q; Zeng W; Zaslavsky E; Chen JJ; Frohman MA; Golightly MG; Madajewicz S; Chen WT
Int J Cancer; 2010 Feb; 126(3):669-83. PubMed ID: 19662651
[TBL] [Abstract][Full Text] [Related]
69. Identification of novel markers that outperform EpCAM in quantifying circulating tumor cells.
Kim MJ; Choi NY; Lee EK; Kang MS
Cell Oncol (Dordr); 2014 Aug; 37(4):235-43. PubMed ID: 25001871
[TBL] [Abstract][Full Text] [Related]
70. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
71. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
[TBL] [Abstract][Full Text] [Related]
72. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases.
Cimino A; Halushka M; Illei P; Wu X; Sukumar S; Argani P
Breast Cancer Res Treat; 2010 Oct; 123(3):701-8. PubMed ID: 20012351
[TBL] [Abstract][Full Text] [Related]
73. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
Schmidt M; Scheulen ME; Dittrich C; Obrist P; Marschner N; Dirix L; Schmidt M; Rüttinger D; Schuler M; Reinhardt C; Awada A
Ann Oncol; 2010 Feb; 21(2):275-282. PubMed ID: 19633042
[TBL] [Abstract][Full Text] [Related]
74. Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer.
Singh A; Denu RA; Wolfe SK; Sperger JM; Schehr J; Witkowsky T; Esbona K; Chappell RJ; Weaver BA; Burkard ME; Lang JM
Mol Oncol; 2020 Aug; 14(8):1898-1909. PubMed ID: 32255253
[TBL] [Abstract][Full Text] [Related]
75. Detection of circulating tumor cells and tumor stem cells in patients with breast cancer by using flow cytometry: a valuable tool for diagnosis and prognosis evaluation.
Wang N; Shi L; Li H; Hu Y; Du W; Liu W; Zheng J; Huang S; Qu X
Tumour Biol; 2012 Apr; 33(2):561-9. PubMed ID: 22241087
[TBL] [Abstract][Full Text] [Related]
76. The clinical utility of circulating tumor cells in breast cancer patients: detection by a quantitative assay of h-MAM gene expression.
Cheng M; Chen Y; Zou D; Shen G; Bian G; Shen G; Hu S
Int J Biol Markers; 2014 Sep; 29(3):e268-78. PubMed ID: 24706379
[TBL] [Abstract][Full Text] [Related]
77. EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale.
Herreros-Pomares A; Aguilar-Gallardo C; Calabuig-Fariñas S; Sirera R; Jantus-Lewintre E; Camps C
Crit Rev Oncol Hematol; 2018 Jun; 126():52-63. PubMed ID: 29759567
[TBL] [Abstract][Full Text] [Related]
78. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis.
Spizzo G; Fong D; Wurm M; Ensinger C; Obrist P; Hofer C; Mazzoleni G; Gastl G; Went P
J Clin Pathol; 2011 May; 64(5):415-20. PubMed ID: 21415054
[TBL] [Abstract][Full Text] [Related]
79. Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1.
Bartkowiak K; Mossahebi Mohammadi P; Gärtner S; Kwiatkowski M; Andreas A; Geffken M; Peine S; Verpoort K; Scholz U; Deutsch TM; Michel LL; Schneeweiss A; Thewes V; Trumpp A; Müller V; Riethdorf S; Schlüter H; Pantel K
J Proteome Res; 2023 Apr; 22(4):1213-1230. PubMed ID: 36926972
[TBL] [Abstract][Full Text] [Related]
80. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.
Farace F; Massard C; Vimond N; Drusch F; Jacques N; Billiot F; Laplanche A; Chauchereau A; Lacroix L; Planchard D; Le Moulec S; André F; Fizazi K; Soria JC; Vielh P
Br J Cancer; 2011 Sep; 105(6):847-53. PubMed ID: 21829190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
